New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BRCM;GILD;GE;BA;DVAX;CSCO;WPRT;CELG;DKS;CLNE;EXEL;HD;SODA;O;SAND;QCOM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
October 13, 2014
07:56 EDTGILDGilead Harvoni pricing 'very reasonable,' says RBC Capital
Subscribe for More Information
07:39 EDTGILDPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
07:26 EDTBACommercial aerospace stocks should be bought on any weakness, says Wells Fargo
Subscribe for More Information
06:04 EDTDVAXDynavax initiates Phase 1/2 study of TLR-9 agonist
Subscribe for More Information
October 12, 2014
19:41 EDTBABoeing and Garuda Indonesia announce $4.9B order
Subscribe for More Information
17:41 EDTGEGeneral Electric could return 25%, Barron's says
Subscribe for More Information
17:20 EDTQCOM, CSCO, GEGE, Splunk, Cisco, others could benefit from Internet of Things, Barron's says
Subscribe for More Information
October 10, 2014
18:51 EDTBADOJ orders Boeing to pay $23M to resolve False Claims Act allegations
Subscribe for More Information
18:05 EDTGEGeneral Electric negotiating deal to buy Milestone Aviation, WSJ reports
General Electric's finance unit is negotiating a deal to acquire Milestone Aviation Group, and the purchase price could be more than $2.5B, The Wall Street Journal reports, citing people familiar with the matter. Reference Link
14:08 EDTGILDGilead 12-week regimen of Harvoni to cost $94.5K
Gilead said its newly-approved treatment of hepatitis C genotype 1 infection, Harvoni, will be priced at $94,500 for a full 12 week regiment, according to multiple media outlets, which cite a company spokesperson.
13:55 EDTGILDGilead confirms FDA approval of Harvoni
Subscribe for More Information
13:42 EDTGILDGilead hepatitis C treatment Harvoni approved by FDA
The FDA announced the approval of Harvoni to treat chronic hepatitis C virus genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection, the agency stated. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection, it added. Harvoni is marketed by Gilead.
13:40 EDTGILDFDA approves Gilead hepatitus C treatment Harvoni
Subscribe for More Information
09:08 EDTHDHome Depot management to meet with Deutsche Bank
Subscribe for More Information
08:41 EDTCELGCelgene reports apremilast significantly improved preexisting psoriasis in study
Subscribe for More Information
08:39 EDTCELGCelgene says data show Apremilast treatment resulted in improved quality of life
Subscribe for More Information
08:19 EDTGILDMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
07:25 EDTGEGE CEO to continue shedding divisions in FY15, Bloomberg says
Subscribe for More Information
07:21 EDTGEGE expects data division to exceed $1B in sales this year, Reuters says
GE CEO Jeff Immelt said that the company was en route to gross over $1B in sales from its industrial data-analysis division in FY14, and is looking to broaden the availability of its software platform in FY15, according to Reuters, citing comments from Immelt. Reference Link
07:21 EDTGILDFDA PDUFA Date for Gilead Sciences Sofosbuvir is October 10, 2014
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use